bgb-11417,zanubrutinib
beigene
['zanubrutinib', 'lymphoma', 'bgb-11417', 'nhl', 'hodgkin']
#ash22 | hall d | monday 6pm cst
a phase 1 study with the novel b-cell lymphoma 2 (bcl-2) inhibitor bgb-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-hodgkin lymphoma (nhl) or waldenstr m macroglobulinemia (wm): preliminary data 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.